FindTrial
Sign In

Fukuoka study of ipraglifrozin

Fukuoka study of ipraglifrozin - FUSION

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000014797
Enrollment
1000
Registered
2014-08-08
Start date
2014-08-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

iproglifrozin 50mg

Sponsors

Fukuoka university, school of medicine, department of endocrinology and diabetes mellitus
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Type 2 diabetes with HbA1c =/> 6.4%

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes 2. Patients with severe renal failure or liver dysfunction 3. Patients with drug allergy for ipraglifrozin 4. Patients with history of diabetec ketosis 5. Patients with shick day

Design outcomes

Primary

MeasureTime frame
Glycemic control Adverse effects—

Secondary

MeasureTime frame
Atherosclerotic markers—

Countries

Japan

Contacts

Public ContactTakashi Nomiyama

Fukuoka university, school of medicine Department of endocrinology and diabetes mellitus

tnomiyama@fukuoka-u.ac.jp092-801-1011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026